One pill is different, orange coloured

Cell-replacement therapy in Parkinson’s involves altering stem cells into dopamine producing nerve cells (or dopaminergic neurons) and transplanting them into a person with Parkinson’s brain to replace dying or lost neurons.

By the time a person is presenting the motor features characteristic of Parkinson’s, and being referred to a neurologist for diagnosis, they have already lost approximately 50% of the dopamine producing neurons in an area of the brain called the midbrain. The dopamine neurons are located in a part of the midbrain called the substantia nigra.

Protoplasmic astrocytes (violet) play an active role in neuronal communication through synapses and regulation of neural circuit functions, memory and learning.

These neurons are critical for normal motor function – without them, movement becomes very inhibited, resulting in the slowness and rigidity associated with Parkinson’s.

And until we have developed methods that can identify Parkinson’s long before these nerve cells are lost and the motor features appear, some form of cell-replacement therapy is required to introduce new cells to take up the lost function.

Cell transplantation represents the most straightforward (but still experimental) method of cell-replacement therapy.

Recent advances in this area of research have shifted away from the old approach to cell transplantation (using dopamine neurons from a donor embryo), and moving towards developing sophisticated methods for growing dopamine-producing neurons in cell culture.

It is important to understand that, by itself, cell transplantation is not curative and will not halt the progression of the condition. It is simply an experimental method of replacing lost nerve cells. There are however promising clinical trials happening now which are testing surgical transplantation of dopamine-producing nerve cells into people with Parkinson’s brains – the results of which will be available in the next few years.


News

Research news

NECTAR 2021

The Network for European CNS Transplantation and Restoration (NECTAR) was founded over 25 years ago. Here, Dr Simon Stott presents a brief update on the events at NECTAR 2021.

News

Research news

More data from the ‘Blue Rockers’

BlueRock Therapeutics has published two preclinical research reports outlining the cell culturing method that they are taking into clinical trials.

Astrocytes

News

Research news

Astrocytes to dopamine neurons in one step

The brain is made up of multiple types of cells. There are the neurons that conduct much of the cognitive functioning in the brain, Then there are a collection…

GDNF and Cell Transplantation

News

Research news

GDNF and cell transplantation: dual therapies for Parkinson’s

Parkinson’s is a complex condition and it is becoming increasingly clear that the future of disease-modifying therapies for Parkinson’s will rely on the use of multiple treatment approaches, as…

News

Research news

The rationale for the TRANSEURO study

The TRANSEURO study is part-funded by Cure Parkinson’s and is investigating dopamine cell replacement therapy as a restorative treatment for people with Parkinson’s.  It is being coordinated by Professor…